Regeneron Pharmaceuticals, Inc. REGN
NASDAQ
| 09/30/2026 | 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | |
|---|---|---|---|---|---|
| Revenue | 15.98B | 14.73B | 14.13B | 13.64B | 13.60B |
| Total Other Revenue | 913.10M | 801.30M | 791.90M | 702.60M | 643.40M |
| Total Revenue | 16.90B | 15.53B | 14.92B | 14.34B | 14.25B |
| Cost of Revenue | 9.00B | 8.63B | 8.37B | 7.95B | 7.72B |
| Gross Profit | 7.90B | 6.91B | 6.55B | 6.39B | 6.53B |
| SG&A Expenses | 2.76B | 2.74B | 2.71B | 2.70B | 2.72B |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | 0.00 | -10.00M | -10.00M | -10.00M | -10.00M |
| Total Operating Expenses | 11.76B | 11.36B | 11.08B | 10.64B | 10.42B |
| Operating Income | 5.13B | 4.17B | 3.84B | 3.70B | 3.82B |
| Income Before Tax | 5.69B | 5.17B | 5.16B | 5.23B | 5.15B |
| Income Tax Expenses | 869.40M | 837.30M | 733.50M | 725.80M | 567.10M |
| Earnings from Continuing Operations | 4.82K | 4.33K | 4.42K | 4.50K | 4.58K |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 4.82B | 4.33B | 4.42B | 4.50B | 4.58B |
| EBIT | 5.13B | 4.17B | 3.84B | 3.70B | 3.82B |
| EBITDA | 5.65B | 4.70B | 4.38B | 4.25B | 4.35B |
| EPS Basic | 46.98 | 41.91 | 42.53 | 43.12 | 43.44 |
| Normalized Basic EPS | 41.33 | 35.19 | 33.11 | 32.21 | 26.79 |
| EPS Diluted | 45.29 | 40.46 | 41.04 | 41.56 | 41.77 |
| Normalized Diluted EPS | 39.81 | 33.92 | 31.89 | 30.99 | 25.72 |
| Average Basic Shares Outstanding | 411.40M | 413.30M | 415.60M | 418.30M | 423.00M |
| Average Diluted Shares Outstanding | 426.80M | 428.40M | 431.00M | 434.50M | 440.80M |
| Dividend Per Share | 3.70 | 3.64 | 3.58 | 3.52 | 2.64 |
| Payout Ratio | 7.95% | 8.74% | 8.46% | 8.22% | 6.06% |